The Efficacy of Lapatinib in Metastatic Breast Cancer with HER2 Non-Amplified Primary Tumors and EGFR Positive Circulating Tumor Cells: A Proof-Of-Concept Study

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Stebbing, Justin ^a   Payne, Rachel ^a   Reise, Justine ^a   Frampton, Adam E ^a   Avery, Miranda ^a   Woodley, Laura ^a   Di Leo, Angelo ^b   Pestrin, Marta ^b   Krell, Jonathan ^a   Coombes, R Charles ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b Istituto Tosacano Tumori   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BREAST METASTASIS; CANCER CHEMOTHERAPY; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROL STRATEGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; HEART EJECTION FRACTION; HUMAN; HYPERBILIRUBINEMIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION; SCREENING TEST; SIDE EFFECT;

EID: 84877144549     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062543     Document Type: Article

References (36)

1. Hahn WC, Weinberg RA, (2002) Rules for making human tumor cells. N Engl J Med 347: 1593-1603.
2. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, et al. (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118: 523-530.
3. Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, et al. (2011) HER2-positive circulating tumor cells in breast cancer. PLoS One 6: e15624.
4. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, et al. (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101: 9393-9398.
5. Yarden Y, Sliwkowski MX, (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
6. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, et al. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10: 331S-336S.
7. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, et al. (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544-5552.
8. Finn RS, Press MF, Dering J, Arbushites M, Koehler M, et al. (2009) Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. J Clin Oncol 27: 3908-3915.
9. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791.
10. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, et al. (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23: 1420-1430.
11. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, et al. (2006) Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 12: 6403-6409.
12. Smith BM, Slade MJ, English J, Graham H, Luchtenborg M, et al. (2000) Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 18: 1432-1439.
13. Stebbing J, Jiao LR, (2009) Circulating tumour cells as more than prognostic markers. Lancet Oncol 10: 1138-1139.
14. Jacob J, Krell J, Castellano L, Jiao LR, Stebbing J, et al. (2011) Determination of cut-offs for circulating tumor cell measurement in metastatic cancer. Expert Rev Anticancer Ther 11: 1345-1350.
15. Payne RE, Yague E, Slade MJ, Apostolopoulos C, Jiao LR, et al. (2009) Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10: 51-57.
16. Arteaga CL, O'Neill A, Moulder SL, Pins M, Sparano JA, et al. (2008) A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 14: 6277-6283.
17. Polychronis A, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, et al. (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6: 383-391.
18. Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, et al. (2010) Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16: 1904-1914.
19. Liu Z, Fusi A, Schmittel A, Tinhofer I, Schneider A, et al. (2010) Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biol Ther 10: 860-864.
20. Rexer BN, Engelman JA, Arteaga CL, (2009) Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 8: 18-22.
21. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, et al. (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
24. Walker RA, Bartlett JM, Dowsett M, Ellis IO, Hanby AM, et al. (2008) HER2 testing in the UK: further update to recommendations. J Clin Pathol 61: 818-824.
25. Stebbing J, Thiyagarajan A, Surendrakumar V, Payne R, Krell J, et al. (2011) Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk. J Clin Pathol 64: 829-831.
26. Polyak K, (2011) Heterogeneity in breast cancer. J Clin Invest 121: 3786-3788.
27. Rajendra TK, Praveen K, Matera AG, (2010) Genetic analysis of nuclear bodies: from nondeterministic chaos to deterministic order. Cold Spring Harb Symp Quant Biol 75: 365-374.
28. Lydon JP, (2010) Stem cells: Cues from steroid hormones. Nature 465: 695-696.
29. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G, (2005) Breast cancer. Lancet 365: 1727-1741.
30. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, et al. (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140: 62-73.
31. Lorico A, Rappa G, (2011) Phenotypic heterogeneity of breast cancer stem cells. J Oncol 2011: 135039.
32. Hahn WC, Weinberg RA, (2002) Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331-341.
33. Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L, (2007) Using specific cytotoxics with a targeted mind. Breast 16Suppl 2: S120-126.
34. Lyons JG, Lobo E, Martorana AM, Myerscough MR, (2008) Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis 25: 665-677.
35. Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, et al. (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104: 257-263.
36. Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, et al. (2009) Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol 27: 5552-5558.